<?xml version="1.0" encoding="utf-8"?>
<items><story><date>07:16 03 January 2007 (UTC)</date><text>NEW YORK Jan 3 Amylin Pharmaceuticals Inc.
AMLN.O and Eli Lilly and Co. (LLY.N) said on Wednesday that
U.S. regulators approved their Byetta diabetes treatment as an
add-on therapy for type 2 diabetics who have not achieved
blood-sugar control using thiazolidinedione drugs. Doctors and other health-care professionals will be
educated on this additional use for Byetta in the coming weeks,
the companies said.


</text><link>http://www.reuters.com/article/2007/01/03/amylin-lilly-byetta-idUSWEN168120070103</link><sectors><value><value>Regulatory News</value></value></sectors><title>amylin , lilly win added use for diabetes drug</title></story></items>